SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Beyond Meat, Inc. engages in the provision of plant-based meats. Its products include ready-to-cook meat under The Beyond Burger and Beyond Sausage brands, and frozen meat, namely, Beyond Chicken Strips and Beyond Beef Crumbles. The company was founded by Ethan Walden Brown and Brent Taylor in 2009 and is headquartered in El Segundo, CA.

Beyond Meat Inc

Beyond Meat is driving massive community engagement and high-volume trading as investors attempt to spark a short squeeze, fueled by optimism over recent distribution deals and persistent retail buying. While bulls are focused on overcoming technical resistance to avoid a potential reverse split, the stock remains a battlefield between speculative traders banking on a parabolic reversal and bears betting against the company's long-term financial health.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing massive volatility fueled by an extreme short squeeze, with community discussion highlighting highly concentrated ownership and the stock's parabolic price action leading to frequent trading halts. Investors are fiercely debating whether this represents a generational wealth opportunity or a dangerous bubble, as traders compare the chaotic price swings to past meme stock phenomena.

Faraday Future Intelligent Electric, Inc. is an emerging growth company, which manufactures electric vehicles. The company was founded by Jia Yueting in May 2014 and is headquartered in Gardena, CA.

Faraday Future Intelligent Electric Inc - Ordinary Shares - Class A

Faraday Future Intelligent Electric Inc

Faraday Future is seeing a surge in investor attention driven by recent financing news, leadership changes, and a strategic pivot toward embodied AI and robotics, sparking intense debate among those positioning for a potential squeeze and those skeptical of the company's long-term financial stability. While bullish sentiment centers on the stock's historical volatility and expansion into new growth sectors, many community members remain cautious, focusing on the history of dilution, reverse split proposals, and the company's path to regain compliance.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending due to its expanded collaboration with NVIDIA to integrate the QNX operating system into industrial, medical, and robotics AI platforms, signaling a successful pivot toward high-growth edge computing. The community is actively discussing the stock's multi-year turnaround, high trading volume, and potential for long-term valuation growth as retail and institutional investors react to its strengthening partnerships.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing significant investor attention as community members discuss a potential breakout driven by strong volume and expectations for a major turnaround ahead of the upcoming earnings release. The stock is currently a hot topic for debate, with many traders focused on its ability to sustain a push above key technical resistance levels while bulls highlight the company's aggressive talent acquisition and AI-focused mortgage strategy.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently oscillating as traders react to shifting sentiment around the Clarity Act and broader crypto market volatility tied to Bitcoin's price action. Community discussions remain polarized, with many investors closely monitoring technical support levels near 200 while debating whether potential legislative breakthroughs will provide the catalyst needed to break out of recent trading ranges.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending as investors react to a strategic pivot toward aerospace and defense manufacturing, punctuated by a significant multi-year contract with the Defense Logistics Agency and a growing backlog of mission-critical defense projects. The community is actively discussing the stock's potential for a short squeeze amid high short interest and speculative momentum surrounding the company's role in the manufacturing supply chains for high-profile aerospace partners.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as traders digest the surprise announcement of a CEO transition, with hardware chief John Ternus set to succeed Tim Cook in September. Market discourse is heavily split between optimism over a potential innovation reset and concerns regarding near-term uncertainty, with the community actively debating whether the move is a proactive long-term play or a reaction to leadership and regulatory headwinds.

La Rosa Holdings Corp. operates as a holding company, which provides real estate brokerage services. It sells technology-based products and services primarily to sales agents and the sales agents associated with its franchisees. The company operates through the five reportable segments: Residential Real Estate Brokerage Services, Franchising Services, Coaching Services, Property Management, and Commercial Real Estate Brokerage Services. The Residential Real Estate Brokerage Services segment engages in the real estate brokerage business. The Franchising Services segment engages in the franchising of real estate brokerage agencies. The Coaching Services segment engages in the delivery of coaching services to its brokers and franchisee's brokers. The Property Management segment engages in the training of its sales agents to provide residential property management services to owners of single family residential properties. The Commercial Real Estate Brokerage Services segment engages in the brokering of the sale of commercial real estate. La Rosa Holdings was founded by Joseph La Rosa in 2004 and is headquartered in Celebration, FL.

La Rosa Holdings Corp

La Rosa Holdings is trending as investors weigh the potential impact of its non-binding agreement to acquire Consensus Core Technologies, a move that would pivot the company into the competitive AI data center and infrastructure space. While some community members are highlighting the stock's low float and speculative upside as a potential reversal play, others are expressing skepticism, focusing on the company's history of dilution and persistent downward price action.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as frustrated investors react to a relentless rally in semiconductor stocks, which has defied bearish expectations and resulted in significant losses for those betting on a sector pullback. The community is actively debating the merits of capitulation versus doubling down, with many expressing shock at the lack of a downward correction despite ongoing geopolitical tensions and overbought technical indicators.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Volume Explodes, Fundamentals Shift

Today’s market action reflects a striking divergence between speculative momentum, restructuring narratives, and long-term industrial themes. $OMEX, $KBLB, $UCAR, $ELAB, $BBGI, $QNCX

Quince Therapeutics Stock Climbs 8% Over Payment Of $5.5 Mln To Settle EIB Loan

(RTTNews) - Shares of Quince Therapeutics, Inc. (QNCX) are moving up about 8 percent on Monday morning trading after the company announced the settlement of its outstanding obligations under its loan from the European Investment Bank for a payment of $5.5 million...

<ul class="summary-bullets"><li>Quince Therapeutics paid $5.5 million to settle its total debt worth $16.4 million.</li><li>The company had earlier said that it has a runway up to the second half of 2026 if its warrants are exercised.</li><li>The stock has tanked 97% since the company announced disappointing trial results for its treatment of a rare nervous system disorder.</li></ul>Shares of Quince Therapeutics (QNCX) gave up most of their pre-market gains, but traded with almost 10% gains on Monday morning after the company announced it has settled its debt with the European Investment Bank, a move that clears the way for advancing its restructuring efforts.Quince Therapeutics said it paid $5.5 million and, as a result, has settled its total debt worth $16.4 million. With this payment, all commitments under both the loan and settlement agreements have been fully satisfied.“By settling Quince’s debt obligations, we believe that we have removed a substantial overhang that was constraining the company’s flexibility and ability to pursue strategic alternatives, including, but not limited to, merger, reverse merger, asset sale, or other strategic transactions,” said CEO Dirk Thye.&nbsp;The company had earlier appointed LifeSci Capital as its exclusive financial advisor to assist with the restructuring.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.Users speculated a potential merger after the debt was cleared.<stembedurl>https://stocktwits.com/SuellenD/message/648925162</stembedurl><stembedurl>https://stocktwits.com/andrew011/message/648923227</stembedurl><h2 class="st-heading-2">Stock Sinks After Disappointing Phase 3 Results</h2>In January, Quince Therapeutics’ Phase 3 NEAT trial evaluating eDSP in patients with Ataxia-Telangiectasia, a rare disorder impacting the nervous and immune systems, missed its primary and key secondary endpoints. <a href="https://stocktwits.com/symbol/QNCX">QNCX stock</a> has since crashed more than 97%.According to its last financial filing for the quarter ended Sept. 30, 2025, the company reported $26.3 million in cash and investments. The funds are expected to support operations through the second quarter of 2026, but could be extended into the second half of 2026 if its warrants are fully exercised.Last year, the company raised about $11.5 million in upfront funding through a financing round, with the potential to secure an additional $10.4 million if the associated warrants are fully exercised for cash.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tariff uncertainty has prompted several analysts to cut their price targets for Five9 stock. 

QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger

Quince Therapeutics Inc (QNCX) cleared a key debt obligation with the European Investment Bank, a move allowing it to pursue strategic restructuring. 

Equity

The company cleared a key debt obligation with the European Investment Bank, a move allowing it to pursue strategic restructuring. 

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the companys outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5...

What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours

Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capital as financial advisor amid restructuring and strategic plans. read more...

Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today

QNCX, SPOT, SPGI, INTC, DDOG were among the stocks trending among investors on Tuesday, Feb. 10, 2026.read more...

<ul class="summary-bullets"><li>The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to Quince Therapeutics.</li><li>On January 29, QNCX shares plunged 91.5% after the company said it would halt clinical development of its lead asset Edsp.</li><li>Lucid Capital double-downgraded Quince Therapeutics to ‘Sell’ from ‘Buy’ late last month.</li></ul>Shares of Quince Therapeutics, Inc. (QNCX) surged nearly 60% in pre-market trading on Tuesday after the company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to the company. In addition to assessing these opportunities, LifeSci Capital will advise Quince Therapeutics on any potential restructuring of its liabilities.Quince, a late-stage biotechnology firm focusing on rare disease treatments, added that it will not provide updates during the review and will disclose developments only if its board approves a specific action or deems further communication necessary.<h2 class="st-heading-2">96% Market Value Erased In Just Over A Week</h2>Quince Therapeutics’ stock has been under heavy selling pressure lately. On January 29, QNCX shares plunged 91.5% after the company <a href="https://stocktwits.com/news-articles/markets/equity/qncx-stock-plummets-over-90-percent/cmyipqPR410">said</a> it would halt clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).The late-stage trial in 105 patients with Ataxia-Telangiectasia, a rare and inherited neurodegenerative disorder, did not meet statistical significance for its primary endpoint. The study also missed its key secondary goal. The stock declined a further 37% in the following session.<a href="https://stocktwits.com/symbol/QNCX">QNCX shares</a> have declined nearly 96% from January 28 to Monday’s close.<h2 class="st-heading-2">Wall Street Turns Bearish</h2>The results prompted Lucid Capital to double downgrade Quince Therapeutics to ‘Sell’ from ‘Buy’ with a price target of $0, down from $8. The firm noted that the program, which is Quince’s asset, will be discontinued, and, given that the company’s estimated cash and long-term debt are nearly equal, it sees no value in the shares.The company has also faced mounting financial pressure. In the third quarter of fiscal 2025, Quince reported a net loss of $13.3 million, more than quadrupling the $3.2 million loss from a year earlier. Total operating expenses jumped 130% to $13.4 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/QNCX_jpg_46df9654d8.webp" alt="QNCX.jpg" width="927" height="111"><figcaption>QNCX's Sentiment Meter and Message Volumes at Premarket on Feb. 10, 2026 | Source: Stocktwits</figcaption></figure>One bullish user noted the high volumes in after-market trading.<stembedurl>https://stocktwits.com/Risley/message/644527590</stembedurl>However, one bearish user highlighted the company’s shortcomings in the clinical trial.<stembedurl>https://stocktwits.com/Marceltrade/message/644532523</stembedurl>Over the past year, the stock has slumped 91%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-subdued-tsla-rblx-tsm-hood-kd-stocks-to-watch/cZbUbhPR4Y9">Nasdaq, S&amp;P 500 Futures Subdued After Dow Closes Above 50,000: Why TSLA, RBLX, TSM, HOOD, KD Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout?

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.

This Nano-Cap Biotech Stock Soars 60% Pre-Market Just Days After A Near-Total Wipeout – Here’s What’s Driving The Move

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics, Inc. (Nasdaq: QNCX), today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in its restructuring and evaluation of strategic...

Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease

Quince Therapeutics shares plunged nearly 90% after its Phase 3 trial for a rare genetic disorder missed primary and secondary goals, despite showing no major safety concerns.read more...

Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp

Citizens Jmp cut shares of Quince Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday...

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient’s biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Current Price	$1.34
Prev Close	$1.27
Open	$1.28
Dividend Yield	0.00%
50-Day Moving Average	$1.41
Beta	0.99
Avg. Volume	3.69M
PE Ratio	-0.08

52-Week High	$45.50
52-Week Low	$0.80
Market Capitalization	$20.7M
EPS (Annual)	-$16.76
Price to Book	-0.20
Revenue Per Employee	$0.00

QNCX
Quince Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QNCX News

QNCXQuince Therapeutics Inc